Janumet is an anti-diabetic drug owned by Merck Sharp Dohme. It contains active ingredients Metformin Hydrochloride and Sitagliptin Phosphate. This drug was first granted marketing authorization on March 30, 2007. It holds a total of 8 patents, 4 of which have already expired.
The generic version of Janumet is expected to be available after January 21, 2029. This is due to the patent US8414921*PED that holds the exclusivity for the pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin, which will expire on January 21, 2029. Consequently, Janumet generic will likely be released after this date.
Janumet is specifically used for treating type 2 diabetes mellitus. The drug's effectiveness is due to the active ingredients it contains. Sitagliptin Phosphate is a dipeptidyl peptidase-4 inhibitor that aids in controlling high blood sugar which is beneficial for diabetes patients. When combined with metformin or insulin, it can further enhance the patient's ability to control their blood glucose levels.
Janumet holds several patents that contribute to the delay of Janumet generic release. The last patent to expire, US8414921*PED, is about the pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin, which is due to expire on January 21, 2029. Hence, below are the details of the patent: